RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Stock-based compensation

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 2024983+11.05%
Dec 31, 2023885+22.07%
Dec 31, 2022725+20.49%
Dec 31, 2021602+39.28%
Dec 31, 2020432-6.96%
Dec 31, 2019464+8.63%
Dec 31, 2018427-15.75%
Dec 31, 2017507-9.40%
Dec 31, 2016560+21.96%
Dec 31, 2015459+49.41%
Dec 31, 2014307+54.86%
Dec 31, 2013198+110.71%
Dec 31, 201294+67.86%
Dec 31, 201156+40.60%
Dec 31, 201040

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)